Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 143

1.

Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.

Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, Acton RT.

Pharmacogenomics. 2008 May;9(5):511-26. doi: 10.2217/14622416.9.5.511.

PMID:
18466099
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.

Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM.

Blood Cells Mol Dis. 2009 Jul-Aug;43(1):119-28. doi: 10.1016/j.bcmd.2009.01.019. Epub 2009 Mar 17.

PMID:
19297219
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.

Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, Arnett DK, Acton RT, Liu N.

Pharmacogenomics. 2008 Oct;9(10):1445-58. doi: 10.2217/14622416.9.10.1445.

PMID:
18855533
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

New genetic variant that might improve warfarin dose prediction in African Americans.

Schelleman H, Brensinger CM, Chen J, Finkelman BS, Rieder MJ, Kimmel SE.

Br J Clin Pharmacol. 2010 Sep;70(3):393-9. doi: 10.1111/j.1365-2125.2010.03709.x.

PMID:
20716240
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.

Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ.

Pharmacogenomics. 2009 Aug;10(8):1243-55. doi: 10.2217/pgs.09.71.

PMID:
19663669
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.

Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT.

Clin Pharmacol Ther. 2008 Feb;83(2):312-21. Epub 2007 Jul 25.

PMID:
17653141
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.

Kim HS, Lee SS, Oh M, Jang YJ, Kim EY, Han IY, Cho KH, Shin JG.

Pharmacogenet Genomics. 2009 Feb;19(2):103-12. doi: 10.1097/FPC.0b013e32831a9ae3.

PMID:
19077919
[PubMed - indexed for MEDLINE]
8.

Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians.

Schelleman H, Chen Z, Kealey C, Whitehead AS, Christie J, Price M, Brensinger CM, Newcomb CW, Thorn CF, Samaha FF, Kimmel SE.

Clin Pharmacol Ther. 2007 May;81(5):742-7. Epub 2007 Feb 28.

PMID:
17329985
[PubMed - indexed for MEDLINE]
9.

Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.

Shalia KK, Doshi SM, Parikh S, Pawar PP, Divekar SS, Varma SP, Mehta R, Doctor T, Shah VK, Saranath D.

J Assoc Physicians India. 2012 Dec;60:34-8.

PMID:
23781667
[PubMed - indexed for MEDLINE]
10.

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.

Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H.

Pharmacogenet Genomics. 2006 Feb;16(2):101-10.

PMID:
16424822
[PubMed - indexed for MEDLINE]
11.

Influence of CYP2C9 and VKORC1 gene polymorphisms on warfarin dosage, over anticoagulation and other adverse outcomes in Indian population.

Gaikwad T, Ghosh K, Kulkarni B, Kulkarni V, Ross C, Shetty S.

Eur J Pharmacol. 2013 Jun 15;710(1-3):80-4. doi: 10.1016/j.ejphar.2013.04.006. Epub 2013 Apr 16.

PMID:
23602689
[PubMed - indexed for MEDLINE]
12.

Factors influencing warfarin dose requirements in African-Americans.

Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH.

Pharmacogenomics. 2007 Nov;8(11):1535-44.

PMID:
18034618
[PubMed - indexed for MEDLINE]
13.

CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.

Santos PC, Dinardo CL, Schettert IT, Soares RA, Kawabata-Yoshihara L, Bensenor IM, Krieger JE, Lotufo PA, Pereira AC.

Eur J Clin Pharmacol. 2013 Apr;69(4):789-97. doi: 10.1007/s00228-012-1404-5. Epub 2012 Sep 19.

PMID:
22990331
[PubMed - indexed for MEDLINE]
14.

Genetic and clinical determinants influencing warfarin dosing in children with heart disease.

Nguyen N, Anley P, Yu MY, Zhang G, Thompson AA, Jennings LJ.

Pediatr Cardiol. 2013 Apr;34(4):984-90. doi: 10.1007/s00246-012-0592-1. Epub 2012 Nov 25.

PMID:
23183958
[PubMed - indexed for MEDLINE]
15.

Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.

Ekladious SM, Issac MS, El-Atty Sharaf SA, Abou-Youssef HS.

Mol Diagn Ther. 2013 Dec;17(6):381-90. doi: 10.1007/s40291-013-0046-3.

PMID:
23839801
[PubMed - indexed for MEDLINE]
16.

An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.

Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL.

Thromb Haemost. 2008 Aug;100(2):229-39.

PMID:
18690342
[PubMed - indexed for MEDLINE]
17.

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.

Ozer N, Cam N, Tangurek B, Ozer S, Uyarel H, Oz D, Guney MR, Ciloglu F.

Heart Vessels. 2010 Mar;25(2):155-62. doi: 10.1007/s00380-009-1177-7. Epub 2010 Mar 26.

PMID:
20339978
[PubMed - indexed for MEDLINE]
18.

Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation.

Li T, Lange LA, Li X, Susswein L, Bryant B, Malone R, Lange EM, Huang TY, Stafford DW, Evans JP.

J Med Genet. 2006 Sep;43(9):740-4. Epub 2006 Apr 12.

PMID:
16611750
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy.

Spreafico M, Lodigiani C, van Leeuwen Y, Pizzotti D, Rota LL, Rosendaal F, Mannucci PM, Peyvandi F.

Pharmacogenomics. 2008 Sep;9(9):1237-50. doi: 10.2217/14622416.9.9.1237.

PMID:
18781852
[PubMed - indexed for MEDLINE]
Free Article
20.

VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.

Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder JS, Hayden MR, Ross CJ, Carleton BC.

Pediatr Blood Cancer. 2014 Jun;61(6):1055-62. doi: 10.1002/pbc.24932. Epub 2014 Jan 29.

PMID:
24474498
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk